Mina Shrestha

May 30, 2024 | bmjopen.bmj.com | James Thornton |Tyler J. Varisco |Harshil Patel |Mina Shrestha

DiscussionThe requirements and recommendations set forth by the FDA and CDC back in 2016 put a spotlight on the risk involved with coprescribing benzodiazepines and opioids. Since then, there have been studies showing a decline in coprescribing benzodiazepines and opioids.32 33 In our study, benzodiazepines made up the largest proportion of sedatives being prescribed, potentially reflecting the decision to emphasise the risk of coprescribing this medication with opioids.